Elmi Sadr Navid, Mirsharif Seyyedeh Sedigheh, Khadamy Joobin, Lavvaf Samaneh, Hariri Ramyar
Ophthalmology, Semnan University of Medical Sciences, Semnan, IRN.
Clinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, IRN.
Cureus. 2024 Apr 14;16(4):e58223. doi: 10.7759/cureus.58223. eCollection 2024 Apr.
Evaluation of anterior segment parameters is crucial in ophthalmic procedures such as intraocular surgeries and contact lens fitting. However, the use of tropicamide in diabetic patients presents challenges due to its potential impact on biometric measurements. This study aims to investigate and compare the effects of 0.5% and 1% tropicamide on anterior segment parameters in diabetic patients.
This double-masked randomized clinical trial enrolled 98 patients with diabetes mellitus. Participants were randomly assigned to receive either 0.5% or 1% tropicamide. Anterior segment parameters were measured using Pentacam HR (Oculus Optikgeräte GmbH, Wetzlar, Germany) before and 30 minutes after tropicamide administration. Parameters included anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle (ACA), keratometry, central corneal thickness (CCT), white-to-white distance (WTW), and pupillary diameter (PD).
Both concentrations of 0.5% and 1% tropicamide induced significant changes in anterior segment parameters. There was a notable increase in PD (2.99 ± 0.62, 3.11 ± 0.55, respectively, both P-values < 0.001), ACD (both 0.10 ± 0.05, both P-values < 0.001), ACV (16.69 ± 9.56, 17.51 ± 9.26, respectively, both P-values < 0.001), and WTW (0.06 ± 0.14, 0.03 ± 0.30, respectively, both P-values < 0.001), along with a decrease in ACA (-3.50 ± 10.65, -3.30 ± 6.87, P-value < 0.001 and P-value=0.001, respectively), and CCT (-6.10 ± 8.06, -6.39 ± 9.97, respectively, both P-values < 0.001) post-dilation. However, no significant changes were observed in keratometry (front Km (-0.03 ± 0.19, -0.04 ± 0.21, respectively), back Km (0.01 ± 0.05, 0.004 ± 0.05, respectively), P-values> 0.05).
Both concentrations of tropicamide exhibited comparable effects on anterior segment parameters in diabetic patients. These post-dilation changes should be considered for accurate intraocular lens power calculation and decision-making for cataract, phakic intraocular lens, and refractive surgeries.
眼前节参数评估在诸如眼内手术和隐形眼镜验配等眼科手术中至关重要。然而，由于托吡卡胺对生物测量可能产生影响，糖尿病患者使用托吡卡胺存在挑战。本研究旨在调查并比较0.5%和1%托吡卡胺对糖尿病患者眼前节参数的影响。
这项双盲随机临床试验纳入了98例糖尿病患者。参与者被随机分配接受0.5%或1%托吡卡胺。在给予托吡卡胺前及给药后30分钟，使用Pentacam HR（德国韦茨拉尔的Oculus Optikgeräte GmbH公司）测量眼前节参数。参数包括前房深度（ACD）、前房容积（ACV）、前房角（ACA）、角膜曲率测量、中央角膜厚度（CCT）、白到白距离（WTW）和瞳孔直径（PD）。
0.5%和1%两种浓度的托吡卡胺均引起眼前节参数的显著变化。散瞳后，PD显著增加（分别为2.99±0.62、3.11±0.55，P值均<0.001），ACD增加（均为0.10±0.05，P值均<0.001），ACV增加（分别为16.69±9.56、17.51±9.26，P值均<0.001），WTW增加（分别为0.06±0.14、0.03±0.30，P值均<0.001），同时ACA减小（分别为-3.50±10.65、-3.30±6.87，P值分别<0.001和=0.001），CCT减小（分别为-6.
